- Home
- ALHC vs TARS Comparison
ALHC vs TARS Comparison
Compare ALHC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | TARS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALHC | TARS |
|---|---|---|
| Price | $12.98 | $72.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $23.13 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 5.7M | 668.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 48.21 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $3,948,719,000.00 | $451,360,000.00 |
| Revenue This Year | $33.69 | $56.43 |
| Revenue Next Year | $24.74 | $30.19 |
| P/E Ratio | $58.77 | ★ N/A |
| Revenue Growth | 46.06 | ★ 146.71 |
| 52 Week Low | $12.70 | $48.20 |
| 52 Week High | $25.12 | $85.25 |
Technical Indicators
Market Signals| Indicator | ALHC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 67.35 |
| Support Level | $13.09 | $60.95 |
| Resistance Level | $22.62 | $73.45 |
| Average True Range (ATR) | 0.65 | 3.12 |
| MACD | 0.06 | 0.77 |
| Stochastic Oscillator | 27.75 | 93.70 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.